ReviewCureus2026
Pancreatoduodenectomy for Gastric Cancer With Pancreatic Involvement: Indications, Outcomes, and Prognostic Factors.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatoduodenectomy (PD) is rarely indicated for gastric cancer because of its high morbidity and uncertain survival benefit; however, in selected patients with gastric cancer and pancreatic involvement, PD may be required to achieve complete oncologic resection. This narrative review summarizes current evidence regarding indications, outcomes, and prognostic factors associated with PD in gastric cancer with pancreatic invasion. A narrative review of the literature was conducted focusing on published series evaluating clinicopathologic features, surgical management, perioperative outcomes, survival, and prognostic factors in patients undergoing PD for gastric cancer with pancreatic involvement. Pancreatic involvement is an uncommon finding in gastric cancer; however, PD is considered only in carefully selected patients when direct pancreatic invasion precludes margin-negative resection with standard gastrectomy. Tumors are most frequently located in the distal stomach and gastric antrum and are typically associated with advanced local disease. Preoperative imaging and intraoperative assessment have limited accuracy in distinguishing true pancreatic invasion from inflammatory adhesions, making histopathologic confirmation essential. Across published series, R0 resection can be achieved in a substantial proportion of patients; however, postoperative morbidity remains considerable, with pancreatic fistula being the most commonly reported complication. Long-term survival outcomes are highly variable and appear to be primarily influenced by tumor biology and the achievement of margin-negative resection. Consistently, the achievement of R0 resection emerges as the most important favorable prognostic factor. PD should not be routinely performed for gastric cancer but may be justified in carefully selected patients with pancreatic invasion when required to achieve complete oncologic resection, with outcomes driven more by oncologic factors than by the extent of surgery itself.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.